Navigation Links
Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis
Date:5/15/2009

and medical equipments, based on its core technologies of high polymer synthesis. The company holds approximately 60% share of the global market for polarizing films. Polarizing film is a core material used in liquid crystal display television production. Nitto Denko's applied products are widely used in medical instruments, automobiles and electronics, accounting for 70% of its total sales. The company remains focused on attaining "Global Niche Top" status in many of its core products. The company has 10 divisions and consolidated group sales in fiscal year 2007 amounted to US$7.45 billion. Additional information about Nitto Denko Corporation is available at www.nitto.com.

KINOVATE LIFE SCIENCES, INC. FORWARD-LOOKING STATEMENT
This press release contains forward looking statements concerning research & development of polymer materials related to the life sciences area developed and commercialized by Kinovate Life Sciences Inc. and its affiliates, including solid support for oligonucleotide synthesis. Any and all statements concerning Kinovate's claims, intentions, beliefs, etc should be considered forward looking statements and as such at-risk. Statements made above, including those concerning testing results should be considered observed values, not guaranteed values, and actual results may differ materially from those mentioned above. Readers of this press release are cautioned to not rely solely on the forward-looking statements contained above.

Kinovate Life Sciences, Inc. is a wholly owned subsidiary of Nitto Denko Corporation.

CONTACTS:
For Kinovate Life Sciences:
Gaby Silver
Marketing Manager, Kinovate Life Sciences, Inc.
Phone: +1-760-435-7042
E-mail: gaby_silver(at)gg.nitto.co.jp
Web : www.kinovate.com

# # #
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Pressure BioSciences, Inc. Provides Corporate Update
2. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
3. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company License to Certain Alzheimers Patents and Patent Applications
4. Abbott Completes Acquisition of Ibis Biosciences, a Subsidiary of Isis
5. Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus
6. BioTime CEO Dr. Michael West Announces the Launch of New Products and Discusses the State of the Stem Cell Industry under the Obama Administration at the Wisconsin Academy of Sciences, Arts, and Letters
7. Intellect Neurosciences, Inc. Validates Pivotal European Patent for Alzheimers Monoclonal Antibody Platform
8. Intellect Neurosciences, Inc. Grants to Top Tier Global Pharmaceutical Company an Option to License Certain Alzheimers Patents and Patent Applications
9. [video] Hojabr Alimi, CEO of Oculus Innovative Sciences, Inc. Discusses Reduction of Planned Expenses on WallSt.nets 3-Minute Press Show
10. BioTime, Inc. and Embryome Sciences, Inc. Launch Embryome.com and the International Embryome Initiative
11. Coventina Healthcare Enterprises, Inc. is Now ReGear Life Sciences, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... children and adolescents with seizures involving the temporal ... problems and psychiatric illness, especially depression. Findings published ... Wiley on behalf of the International League Against ... evaluation for pediatric epilepsy patientsparticularly for those who ... epilepsy surgery. , Current medical evidence indicates ...
(Date:5/23/2013)... 23, 2013 CareAnyware , ... health and hospice software solutions, and Cornell University ... showed significant reductions in rehospitalization rates for clinically ... Carepath protocol incorporated into CareAnyware’s EMR system. Based ... which included a 39% reduction in rehospitalization rates ...
(Date:5/23/2013)... Lotus Valve, a second-generation transcatheter aortic valve implantation ... the first 60 patients in results from REPRISE ... device performance and low mortality at 30 days., ... but there are opportunities for improvement," explained lead ... and Professor of Medicine, Monash University, Melbourne, Australia. ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... Medicus Ltd. (ASX: PME), announced today that they ... available on the Apple App Store*. When used in ... Platform, Visage Ease provides authorized healthcare providers simple mobile ... Touch iOS devices. , In addition to numerous enhancements ...
(Date:5/23/2013)... 2013 Registered Dietitian and Founder of ... today on Tatalou.com offering helpful tips for travelers who ... titled “ How to Stay Healthy While Traveling ,” ... sanitizer, when it’s safe to drink the water when ... importance of staying hydrated and how taking health supplements ...
Breaking Medicine News(10 mins):Health News:Depression common among children with temporal lobe epilepsy 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 3Health News:Second-generation TAVI device -- Lotus Valve -- shows good performance in REPRISE II 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 3Health News:How to Stay Healthy While Traveling 2
... and Rainbow,Kitchen Community Services announced today that they ... Against Hunger" on Saturday, April 26, 2008.,The event ... and services, and raises public awareness about the,benefits ... participants can either walk or ride bicycles,along the ...
... April 24 Prime Therapeutics (Prime), a,thought leader ... RPh, has joined the organization as Vice President ... Pharmacy Trade Relations, Wan will focus on,developing and ... Prime,s efforts in the development of strategic pharmacy,contracts ...
... Frankfurt: I7VF), INVERNESS, Scotland, April 24 /PRNewswire-FirstCall/ - ... sheet restructuring,leaving it free of all loan note indebtedness, ... to enable it to move forward. The Company has,been ... 2005., Medical Diagnostic Innovations Ltd, a UK investment ...
... (Nasdaq: STAA ) today announced that it will ... 2008 on Tuesday, May 6, 2008,after the market close. ... Tuesday, May 6, 2008 at 5:00 p.m. Eastern Time ... The dial-in number for,the conference call is 866-250-3615 for ...
... 24 The Quigley,Corporation (Nasdaq: QGLY ) today ... the first quarter ended March 31, 2008,compared to $6.1 ... The first quarter of 2008 reflects a net sales ... compared to the first quarter,of 2007. The change during ...
... ) announced that it will release first quarter 2008,financial results on Thursday, ... The Company will host a conference call to discuss the first ... First Quarter 2008 Earnings Conference Call, ... Thursday, May 1, 2008 at 5:00 p.m. Eastern Time, Dial-in: ...
Cached Medicine News:Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 3Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 2Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 3Health News:STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 5
(Date:5/22/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that the Company will present at the Stifel Dental ... the Le Parker Meridian hotel, 119 W. 56 th ... presentation is scheduled to begin at 2:15 p.m. Eastern Time ... Heska Corporation (NASDAQ: HSKA - News) sells ...
(Date:5/22/2013)... Conn. , May 22, 2013 /PRNewswire-iReach/ -- ... stay aligned with the latest trends and events, ... that can predict where an industry is headed ... evolve. (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... partnership with market research publisher GlobalData, offer decision ...
(Date:5/22/2013)... May 22, 2013   Accuray Incorporated (Nasdaq: ... is scheduled to present at the 2013 Jefferies Global ... on Thursday, June 6, 2013 at 1:30 p.m. EDT/10:30 ... presentation will be available online from the Investor Relations ... The webcast replay of the presentation will begin ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4
... 15 Researchers at the Barbara,Ann Karmanos Cancer ... developed a HER2 DNA vaccine that has shown ... The study was reported in the September 15 ... Association for Cancer,Research., ( http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELO ,GO), ...
... women each year than all cancers combined. Although ... patients, the,unique risk factors and symptoms of female ... disease particularly challenging., Data from the WOMEN ... in WomeN presented today at the American Society ...
Cached Medicine Technology:DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers 2What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study 2
The ArthroPasser easily passes any type of suture through tissue and its smooth jaw assists in eliminating,suture fraying....
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 right angled suture passer....
45 right angled suture passer....
Medicine Products: